SIGA Technologies (SIGA) vs Vicore Pharma AB (VCRE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Vicore Pharma AB is the larger company by market cap ($248.4 million vs $235.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SIGA | VCRE |
|---|---|---|
| Share price | $3.28 | $8.82 |
| Market cap | $235.67M | $248.41M |
| 1-day change | +0.61% | +1.85% |
| YTD return | -46.32% | — |
| 1-year return | -60.39% | — |
| 5-year return | -53.87% | — |
| Forward P/E | 3.04 | — |
| EPS (TTM) | $-0.04 | $-2.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.55 | $17.80 |
| 52-week low | $2.83 | $7.88 |
| Distance from 52-week high | -61.64% | -50.45% |
| Analyst consensus | none | none |
| Avg. price target upside | — | +275.96% |
| Average volume | 726.75K | 16.22K |
| Shares outstanding | 71.85M | 28.16M |
| Employees | 49 | 46 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About SIGA Technologies
SIGA stock →SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security market in the United States. The company's lead product is TPOXX, an antiviral drug for the treatment of human smallpox disease caused by variola virus.
Health Care · Biotechnology: Pharmaceutical Preparations · 49 employees
About Vicore Pharma AB
VCRE stock →Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases in Sweden. The company develops Buloxibutid (C21), an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial for treating pulmonary hypertension.
Health Care · Biotechnology: Pharmaceutical Preparations · 46 employees
SIGA vs VCRE FAQ
Which is bigger, SIGA Technologies or Vicore Pharma AB?
Vicore Pharma AB (VCRE) is larger, with a market capitalization of $248.41M compared with $235.67M for SIGA Technologies (SIGA).
Are SIGA Technologies and Vicore Pharma AB in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.